We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 26

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in

Canadian patent term extension is coming

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian

The Myriad decision: what is the impact?

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013

Europe discards embryonic stem cell patents

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • December 15 2011

Adult stem cells, and processes for their manipulation, are generally patentable in Europe

Subsequent entry biologics in Canada: competition vs. exclusivities

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • February 13 2012

Canada has approved the subsequent entry biologic (SEB), Omnitrope (somatropin), following in the footsteps of the U.S. and European approvals

Good news for the biotech industry patent eligibility of Myriad isolated DNA and methods of screening claims confirmed after Supreme Court’s Mayo ruling

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • August 20 2012

On August 16, 2012, the U.S. Federal Circuit Court of Appeals issued its judgment in Association for Molecular Pathology (AMP) and ACLU v. USPTO and Myriad Genetics (Myriad) partly overturning the district court’s summary judgment that Myriad’s claims were drawn to patent ineligible subject matter and affirmed Myriad’s right to patent isolated DNA of BRCA1 and BRCA2, two genes linked to breast and ovarian cancer

Supreme Court of Canada denies leave to appeal in PM(NOC) judicial comity case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • May 9 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Allergan Inc. et al ats. Apotex Inc

Supreme Court declines to hear Eli Lilly’s “promise of the patent” appeal

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • May 16 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Eli Lilly Canada Inc v Novopharm Ltd

Billion dollar drug litigation opens a front in Canada

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 6 2012

Amgen recently started litigation against Teva over the biologic drug filgrastim (Court File No. T-989-12

Dosage regimens in Canada: patentable subject matter?

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • April 10 2012

It is well known that methods of medical treatment do not constitute patentable subject matter in Canada